Valion Bio, Inc. is a clinical-stage immunotherapeutics company focused on developing Entolimod, a Toll-like Receptor 5 agonist aimed at activating the innate immune system. The primary application of Entolimod is for the treatment of Acute Radiation Syndrome (ARS), with additional uses in oncology supportive care for chemotherapy- and radiation-induced neutropenia. Valion Bio also operates Velocity Bioworks, a contract development and manufacturing organization that provides biomanufacturing services to external biotech clients while supporting Valion's supply chain. The company engages with U.S. government agencies for biodefense initiatives and has received FDA designations for its lead product.
- Website
- valionbio.com
- Issuer profile
- All listings